OOIR: Observatory of International Research

Papers

(The TQCC of Hematological Oncology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Cutaneous T‐cell lymphomas—An update 2021	48
Langerhans cell histiocytosis: Version 2021	39
Circ_0009910 shuttled by exosomes regulates proliferation, cell cycle and apoptosis of acute myeloid leukemia cells by regulating miR‐5195‐3p/GRB10 axis	38
Bispecific antibodies for the treatment of lymphomas: Promises and challenges	29
A real‐world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma	26
Real‐life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B‐cell lymphomas	26
Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta‐analysis of randomized clinical trials	25
Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine‐treated, interimPET‐negative classical Hodgkin Lymphoma patients: A radio‐genomic study	22
FIRST‐IN‐HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS‐3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS	21
SARS‐CoV‐2 vaccine response in CAR T‐cell therapy recipients: A systematic review and preliminary observations	20
Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience	20
Hsa_circ_0002483 regulates miR‐758‐3p/MYC axis to promote acute myeloid leukemia progression	19
COVID‐19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients	18
BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL	18
Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B‐cell lymphoma	18
EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL	17
The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphoma	17
NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY	17
Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia	17
Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy	17
INTENSIFIED (INTRAVENOUS AND INTRATHECAL) CNS PROPHYLAXIS IN PRIMARY TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: 5‐YEAR RESULTS OF THE IELSG30 TRIAL	17
The tumor microenvironment of lymphomas: Insights into the potential role and modes of actions of checkpoint inhibitors	17
Obinutuzumab‐related adverse events: A systematic review and meta‐analysis	17
Downregulation of circ_0012152 inhibits proliferation and induces apoptosis in acute myeloid leukemia cells through the miR‐625‐5p/SOX12 axis	16
Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia‐positive acute lymphoblastic leukaemia	15

Prognostic significance of IKZF1 deletions and IKZF1^plus profile in children with B‐cell precursor acute lymphoblastic leukemia treated according to the ALL‐IC BFM 2009 protocol	14
High mortality in fully vaccinated hematologic patients treated with anti‐CD20 antibodies during the “Omicron wave” of COVID‐19 pandemic	14
Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches	14
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R‐CHOP14: A SAKK 38/07 trial post‐hoc analysis	14
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS‐CoV‐2 infection	14
Efficacy and follow‐up of humanized anti‐BCMA CAR‐T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary‐extraosseous, extramedullary‐bone related, and without extramedull	14
THE COMBINATION OF DUVELISIB AND ROMIDEPSIN (DR) IS HIGHLY ACTIVE AGAINST RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA WITH LOW RATES OF TRANSAMINITIS: FINAL RESULTS	14
Chimeric antigen receptor T‐cell therapy combined with autologous stem cell transplantation improved progression‐free survival of relapsed or refractory diffuse large B‐cell lymphoma pat	14
Optimizing CAR T cell therapy in lymphoma	13
LONG‐TERM FOLLOW‐UP OF MULTICENTER PHASE II TRIAL OF ZANUBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX (BOVEN) IN PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL	13
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐	13
CAR T‐cell therapy in large B cell lymphoma	12
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3	12
TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)	12
Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience	12
Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendations	12
Brentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study	12
Salvage therapy with “Dara‐KDT‐P(A)CE” in heavily pretreated, high‐risk, proliferative, relapsed/refractory multiple myeloma	12
Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy	11
Initial results of a multicenter phase 2 study of venetoclax in combination with R‐CHOP (VR‐CHOP) for patients with Richter Syndrome	11
The evolving therapy of DLBCL: Bispecific antibodies	11
GLOFITAMAB MONOTHERAPY INDUCES DURABLE COMPLETE REMISSIONS AND HAS A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RICHTER’S TRANSFORMATION	11
GENETIC SUBTYPE GUIDED RITUXIMAB‐BASED IMMUNOCHEMOTHERAPY IMPROVES OUTCOME IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA: FIRST REPORT OF A RANDOMIZED PHASE 2 STUDY	11
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID‐19 pandemic and at the start of the vaccination program. A Campus CLL report	11
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients	11
Mantle cell lymphoma—Advances in molecular biology, prognostication and treatment approaches	10
KT‐413, A NOVEL IRAKIMID DEGRADER OF IRAK4 AND IMID SUBSTRATES, HAS A DIFFERENTIATED MOA THAT LEADS TO SINGLE‐AGENT AND COMBINATION REGRESSIONS IN MYD88^MT LYMPHOMA MODELS	10
Sinonasal B‐cell lymphomas: A nationwide cohort study, with an emphasis on the prognosis and the recurrence pattern of primary diffuse large B‐cell lymphoma	10
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant	10
NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826	10
Lack of efficacy of convalescent plasma in COVID‐19 patients with concomitant hematological malignancies: An Italian retrospective study	10
Anti‐CD47 immunotherapy in combination with BCL‐2 inhibitor to enhance anti‐tumor activity in B‐cell lymphoma	10
Host‐related factors and cancer: Malnutrition and non‐Hodgkin lymphoma	10
TAFRO syndrome: A disease that known is half cured	9
Elevated serum IL‐13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B‐cell lymphoma	9
Seroconversion and kinetic of anti SARS‐COV‐2 antibodies in 25 patients with hematological malignancies who recovered from SARS‐COV‐2 infection	9
CD38 expression is an important prognostic marker in diffuse large B‐cell lymphoma	9
Glofitamab in relapsed/refractory diffuse large B‐cell lymphoma: Real‐world data	9
Review on natural killer/T‐cell lymphoma	9
Allogeneic stem cell transplant in non‐Hodgkin lymphomas: Still an indication?	9
FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR‐T CELLS AND ENROLLED IN DESCAR‐T REGISTRY, A FRENCH REAL‐LIFE DATABASE FOR CAR‐T CELLS IN HEMATOLOGIC MALIGNANCIES	9
Comparing apples and oranges: The ZUMA‐7, TRANSFORM and BELINDA trials	9
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience	9
Effectiveness of a third dose of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine over a 6‐month follow‐up period in allogenic hematopoietic stem cells recipients	8
The superiority of Epstein‐Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV‐positive NK‐cell lymphoproliferative diseases	8
The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor‐based regimens as induction tre	8
GENETIC MARKERS AND OUTCOME WITH FRONT LINE OBINUTUZUMAB PLUS EITHER CHLORAMBUCIL OR VENETOCLAX ‐ UPDATED ANALYSIS OF THE CLL14 TRIAL	8
Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and meta‐analysis	8
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia	8
GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA	8

DNA damage accumulation and repair defects in FLT3‐ITD acute myeloid leukemia: Implications for clonal evolution and disease progression	8
Bosutinib in the real‐life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine‐kinase inhibitors	8
VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY	8
Global burden and attributable risk factors of acute lymphoblastic leukemia in 204 countries and territories in 1990–2019: Estimation based on Global Burden of Disease Study 2019	8
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients	8
Predictors of clinical evolution of SARS‐CoV‐2 infection in hematological patients: A systematic review and meta‐analysis	8
Successful early treatment combining remdesivir with high‐titer convalescent plasma among COVID‐19‐infected hematological patients	8
Comparison of first‐line treatments of peripheral T‐cell lymphoma according to regimen: A systematic review and meta‐analysis	8
PIRTOBRUTINIB (LOXO‐305), A NEXT GENERATION HIGHLY SELECTIVE NON‐COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDY	8
Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type	8
SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort	8
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controll	8
IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL	8
High inter‐follicular spatial co‐localization of CD8+FOXP3+ with CD4+CD8+ cells predicts favorable outcome in follicular lymphoma	8
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma	7
OFF‐THE‐SHELF CD30.CAR‐MODIFIED EPSTEIN‐BARR VIRUS‐SPECIFIC T CELLS (CD30.CAR EBVSTS) PROVIDE A SAFE AND EFFECTIVE THERAPY FOR PATIENTS WITH HODGKIN LYMPHOMA (HL)	7
Poor survival and prediction of prolonged isolated thrombocytopenia post umbilical cord blood transplantation in patients with hematological malignancies	7
Long term outcomes of gastric mucosa‐associated lymphoid tissue lymphoma treated with radiotherapy: A multi‐center retrospective cohort study	7
Diagnostic strategy for trigger identification in severe reactive hemophagocytic lymphohistiocytosis: A diagnostic accuracy study	7
Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti‐CD19‐chimeric antigen receptor T cells in patients with rela	7
Prognostic value of FDG‐PET/CT response for patient selection before chimeric antigen receptor‐T‐cells therapy in non‐Hodgkin lymphoma	7
FZD6 triggers Wnt–signalling driven by WNT10B^IVS1 expression and highlights new targets in T‐cell acute lymphoblastic leukemia	7
Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B‐cell lymphoma in the rituximab era	7
CHARACTERIZATION OF THE GENETIC LANDSCAPE OF HIGH‐GRADE B‐CELL LYMPHOMA, NOS – AN LLMPP PROJECT	7
Sequencing of myeloma therapy: Finding the right path among many standards	7
Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, non‐inferiority, randomized controll	7
Using natural killer cell‐derived exosomes as a cell‐free therapy for leukemia	7
TNF‐α increases the risk of bleeding in patients after CAR T‐cell therapy: A bleeding model based on a real‐world study of Chinese CAR T Working Party	7
NR1H3 (LXRα) is associated with pro‐inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b‐cell lymphoma	7
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of contr	7
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group	7
VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY	6
Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper	6
CEBPA are independent good prognostic factors in pediatric acute myeloid leukemia	6
Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease	6
Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre‐CAR T‐cell era	6
Molecular classification of aggressive lymphomas—past, present, future	6
A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents	6
What's new in peripheral T‐cell lymphomas	6
Prognostic ability of five clinical risk scores in follicular lymphoma: A single‐center evaluation	6
FIRST IN HUMAN STUDY OF AUTO4, A TRBC1‐TRAGETTING CART T CELL THERAPY IN RELAPSED/REFRACTORY TRBC1‐POSITIVE PERIPHERAL T‐CELL LYMPHOMA	6
CLINICAL ACTIVITY OF LONCASTUXIMAB TESIRINE PLUS IBRUTINIB IN NON‐HODGKIN LYMPHOMA: UPDATED LOTIS 3 PHASE 1 RESULTS	6
Effects of the BTN162b2 mRNA COVID‐19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia	6
First line therapy of CLL	6
Impact of disease status at allogeneic stem cell transplantation on adolescent and young adult patients with early T‐cell precursor acute lymphoblastic leukemia	6
Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant	6
Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management	6
The “m6A writer” METTL3 and the “m6A reader” IGF2BP2 regulate cutaneous T‐cell lymphomas progression via CDKN2A	6
Lower incidence of clinical allergy with PEG‐asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG‐ASP in pediatric patients with acute lymphoblastic leu	6
SINTILIMAB PLUS CHIDAMIDE FOR RELAPSED/REFRACTORY (R/R) EXTRANODAL NK/T CELL LYMPHOMA (ENKTL): A PROSPECTIVE, MULTICENTER, SINGLE‐ARM, PHASE IB/II TRIAL (SCENT)	6
FOURTH GENERATION HUCART19‐IL18 PRODUCES DURABLE RESPONSES IN LYMPHOMA PATIENTS PREVIOUSLY RELAPSED/REFRACTORY TO ANTI‐CD19 CAR T‐CELL THERAPY	6
Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review	6
Pembrolizumab for refractory primary mediastinal B‐cell lymphoma with central nervous system involvement	6
Critical role of the high mobility group A proteins in hematological malignancies	6
Use of serum B‐cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone	6
ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2	6
LOTIS 2 FOLLOW‐UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA	6
EPCORITAMAB MONOTHERAPY AND COMBINATIONS IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR RICHTER’S SYNDROME: NEW ESCALATION AND EXPANSION COHORTS IN EPCORE CLL‐1	6
Metabolic parameters predict survival and toxicity in chimeric antigen receptor T‐cell therapy‐treated relapsed/refractory large B‐cell lymphoma	6
Implication of immune cell signature of tumor microenvironment in diffuse large B‐cell lymphoma	6
Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study	6
Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia (CLL) From a Head‐to‐Head Trial of Acalabrutinib Versus Ibrutinib	6
NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY	6
MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)	6
GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY	5
High‐grade B‐cell lymphomas with MYC and BCL2 translocations lack tumor‐associated macrophages and PD‐L1 expression: A possible noninflamed subgroup	5
PTGDS PROMOTES TUMORIGENESIS OF PERIPHERAL T CELL LYMPHOMA THROUGH REGULATING IRON METABOLISM	5
Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland	5
Gene expression profile unveils diverse biological effect of serum vitamin D in Hodgkin's and diffuse large B‐cell lymphoma	5
Phase II study of fixed‐duration single‐agent ibrutinib in relapsed nodular lymphocyte‐predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group	5
PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DACARBAZINE (N‐AVD) AS FRONTLINE THERAPY IN OLDER ADULTS WITH HODGKIN LYMPHOMA	5
B‐cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non‐Hodgkin's Lymphoma	5
Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B‐Cell lymphoma ‐results of a single center, retrospective	5
High‐risk follicular lymphoma: Treatment options	5
Outcomes of second allogeneic stem cell transplantation and anti‐relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis	5
Intensified conditioning regimens improved disease‐free survival and engraftment after unrelated single‐unit cord blood transplantation but not after matched sibling or matched unrelated donor allogen	5
Growth inhibition and suppression of the mTOR and Wnt/β‐catenin pathways in T‐acute lymphoblastic leukemia by rapamycin and MYCN depletion	5
Impact of initial chemotherapy regimen on outcomes for patients with double‐expressor lymphoma: A multi‐center analysis	5
MOSUNETUZUMAB MONOTHERAPY IN ELDERLY/UNFIT PTS WITH FIRST‐LINE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): SAFETY AND EFFICACY REMAIN PROMISING WITH DURABLE COMPLETE RESPONSES	5
Vulnerabilities in the tumor and microenvironment in follicular lymphoma	5

Post‐transplant lymphoproliferative disease in children, adolescents, and young adults	5
Critical concepts and management recommendations for cutaneous T‐cell lymphoma: A consensus‐based position paper from the Italian Group of Cutaneous Lymphoma	5
IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC	5
Autologous hematopoietic cell transplantation versus whole‐brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta‐analysis	5
Novel agents in relapsed/refractory diffuse large B‐cell lymphoma	5
Outcomes and prognostic factors of adults with refractory or relapsed T‐cell acute lymphoblastic leukemia included in measurable residual disease‐oriented trials	5
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia	5
Outcome of therapy‐related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis	5
OUTCOME OF LARGE B‐CELL LYMPHOMA PATIENTS FAILING CD19 TARGETED CAR‐T THERAPY	5
Advances in positron emission tomography and radiomics	5
SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK	5
LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R MCL: PRIMARY ANALYSIS RESULTS FROM THE MCL COHORT OF THE SINGLE‐ARM, MULTICENTER, SEAMLESS DESIGN TRANSCEND NHL 001 STUDY	5
Primary treatment and recent survival trends in patients with primary diffuse large B‐cell lymphoma of central nervous system, 1995–2016: A population‐based SEER analysis	5
PEMBROLIZUMAB AS FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD‐INELIGIBLE PATIENTS, ALLOWS SUBSEQUENT THERAPY, AND GIVES ADEQUATE SURVIVAL.	5
The role of Vertebral Augmentation Procedures in the management of vertebral compression fractures secondary to multiple myeloma	5
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study	5
FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA	5
Malnutrition diagnosed by GLIM criteria better predicts long‐term outcomes for patients with non‐Hodgkin's lymphoma: A prospective multicenter cohort study	5
Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma	5
Secondary infections worsen the outcome of COVID‐19 in patients with hematological malignancies: A report from the ITA‐HEMA‐COV	5
Are we reaching the maximum cure rate for Hodgkin lymphoma?	5
Upfront identification of high‐risk follicular lymphoma	5
ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDY	5
The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation	5
Is race important in genomic classification of hematological neoplasms?	4
Reappraisal of the role of radiation therapy in lymphoma treatment	4
UPDATED EFFICACY AND SAFETY RESULTS OF ORELABRUTINIB IN THE TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL CELL LEUKEMIA	4
Prognostic factors of children and adolescents with T‐cell acute lymphoblastic leukemia after allogeneic transplantation	4
OUTCOMES IN LATER‐LINES OF THERAPY FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: RESULTS FROM THE INTERNATIONAL SCHOLAR‐5 STUDY	4
COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA	4
Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors	4
Rare lymphomas in routine practice – Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms	4
Elastin MIcrofibriL INterfacer1 (EMILIN‐1) is an alternative prosurvival VLA‐4 ligand in chronic lymphocytic leukemia	4
Nuclear αvβ3 integrin expression, post translational modifications and regulation in hematological malignancies	4
Perirenal and subcutaneous fat differently affect outcomes in newly diagnosed classical Hodgkin lymphoma patients	4
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment	4
Overcoming resistance to anti‐CD19 CAR T‐cell therapy in B‐cell malignancies	4
Diffuse large B‐cell lymphoma	4
ROLE OF MAINTENANCE RITUXIMAB AFTER FIRST‐LINE BENDAMUSTINE + RITUXIMAB OR R‐CHOP IN PATIENTS WITH MANTLE CELL LYMPHOMA FROM A LARGE US REAL‐WORLD COHORT	4
Complications of intracerebroventricular chemotherapy via subgaleal reservoir in primary central nervous system lymphoma: A single‐institution experience on 1247 installations in 94 consecutive patien	4
Non‐overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia	4
Immunophenotype of acute lymphoblastic leukemia in minorities‐ analysis from the SEER database	4
Exosomal NAMPT from chronic lymphocytic leukemia cells orchestrate monocyte survival and phenotype under endoplasmic reticulum stress	4
Cellular therapy in lymphoma	4
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis	4
Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology	4
Downregulation of FAPP2 gene induces cell autophagy and inhibits PI3K/AKT/mTOR pathway in T‐cell acute lymphoblastic leukemia	4
Risk factors for cardiovascular events and mortality in patients diagnosed with diffuse large B‐cell lymphoma and treated with anthracyclines	4
Association of cesarean section with risk of childhood leukemia: A meta‐analysis from an observational study	4
POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA IN THE REAL WORLD	4
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis	4
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement	4
Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemia	4
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells	4
Hepatitis C virus‐associated indolent B‐cell lymphomas: A review on the role of the new direct antiviral agents therapy	4
First in human data of NKX019, an allogeneic CAR NK for the treatment of relapsed/refractory (R/R) B‐cell malignancies	4
D_max: A simple and reliable PET/CT‐derived new biomarker of lymphoma outcome?	4
PRELIMINARY SAFETY DATA FROM PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B‐CELL MALIGNANCIES TREATED WITH THE NOVEL B‐CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB‐11417	4
Lenalidomide treatment for recurrent adult T‐cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation	4
CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)	4
Peripheral T‐cell lymphomas	4
LncRNA FIRRE stimulates PTBP1‐induced Smurf2 decay, stabilizes B‐cell receptor, and promotes the development of diffuse large B‐cell lymphoma	4
Prognostic utility of key copy number alterations in T cell acute lymphoblastic leukemia	4
ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY	4
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid‐19 pandemics	4
TNFRSF13B gene mutation in familial acute myeloid leukemia: A new piece in the complex scenario of hereditary predisposition?	3
Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma	3
Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5‐azacytidine—data from the He	3
DETERMINANTS OF RESISTANCE TO ENGINEERED T‐CELL THERAPIES TARGETING CD19 IN LYMPHOMA	3
15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes: A retrospective single‐center study	3
Long‐term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients	3
The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study	3
EARLY SAFETY AND EFFICACY DATA FROM A PHASE I/II TRIAL OF DZD4205, A SELECTIVE JAK1 INHIBITOR, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA	3
A CONTINUOUS INDIVIDUALIZED RISK INDEX FOR REFINED OUTCOME PREDICTION AFTER TARGETED THERAPY FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CIRI‐CLL)	3
EFFICACY AND SAFETY OF TISAGENLECLEUCEL (TISA‐CEL) IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): PRIMARY ANALYSIS OF THE PHASE 2 ELARA TRIAL	3
Clinical analysis of patients with primary and secondary extranodal natural killer/T‐cell lymphoma of central nervous system	3
Diagnostic relevance of 2‐[¹⁸F]‐FDG PET/CT in patients recently diagnosed with monoclonal gammopathy of undetermined significance	3
CCR7 alterations associated with inferior outcome of adult T‐cell leukemia/lymphoma under mogamulizumab treatment	3
Early granulocyte colony stimulating factor administration increases the risk of cytokine release syndrome in acute lymphoblastic leukemia patients receiving anti‐CD19 chimeric antigen receptor T‐cell	3
A comprehensive analysis of coagulopathy during anti‐B cell maturation antigen chimeric antigen receptor‐T therapy in multiple myeloma, a retrospective study based on LEGEND‐2	3
Pre‐treatment health‐related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA‐BERIT) experienc	3
Risk of a second cancer and infection in patients with indolent B‐cell lymphoma exposed to first‐line bendamustine plus rituximab: A retrospective analysis of an administrative claims database	3
Report of PRPF19 as a novel partner of RARG and the recurrence of interposition‐type fusion in variant acute promyelocytic leukemia	3
EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS	3
A PHASE II TRIAL OF REDUCED DOSE BRENTUXIMAB VEDOTIN FOR CUTANEOUS T‐CELL LYMPHOMAS	3
Does early disease progression predict survival after first line‐treatment of Waldenström macroglobulinemia?	3
SAFETY AND EFFICACY OF CD37‐TARGETING NARATUXIMAB EMTANSINE PLUS RITUXIMAB IN DIFFUSE LARGE B‐CELL LYMPHOMA AND OTHER NON‐HODGKIN’S B‐CELL LYMPHOMAS – A PHASE 2 STUDY	3
Direct‐acting antivirals in hepatitis C virus‐positive mantle cell lymphomas	3
PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38)	3
Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry	3
A PHASE 2 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE (LONCA) VERSUS (VS) IDELALISIB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) – LOTIS‐6	3
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement	3
BASELINE METABOLIC TUMOR VOLUME AND IPS PREDICT ABVD FAILURE IN ADVANCED‐STAGE HODGKIN LYMPHOMA WITH A NEGATIVE INTERIM PET SCAN AFTER 2 CHEMOTHERAPY CYCLES. A RETROSPECTIVE ANALYSIS FROM THE GITIL/FI	3
Predictors of ibrutinib‐associated atrial fibrillation: 5‐year follow‐up of a prospective study	3
Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents	3